NASDAQ:OKYO OKYO Pharma (OKYO) Stock Price, News & Analysis $1.18 +0.01 (+0.85%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About OKYO Pharma Stock (NASDAQ:OKYO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OKYO Pharma alerts:Sign Up Key Stats Today's Range$1.13▼$1.2050-Day Range$0.95▼$1.3352-Week Range$0.81▼$2.12Volume120,140 shsAverage Volume129,907 shsMarket Capitalization$39.93 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company OverviewOKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Read More… The real reason Elon is fully endorsing Trump (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, OKYO Pharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks71st Percentile Overall ScoreOKYO MarketRank™: OKYO Pharma scored higher than 71% of companies evaluated by MarketBeat, and ranked 352nd out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOKYO Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageOKYO Pharma has only been the subject of 1 research reports in the past 90 days.Read more about OKYO Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OKYO Pharma are expected to grow in the coming year, from ($0.40) to ($0.38) per share. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.76% of the float of OKYO Pharma has been sold short.Short Interest Ratio / Days to CoverOKYO Pharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in OKYO Pharma has recently decreased by 11.54%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOKYO Pharma does not currently pay a dividend.Dividend GrowthOKYO Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.76% of the float of OKYO Pharma has been sold short.Short Interest Ratio / Days to CoverOKYO Pharma has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in OKYO Pharma has recently decreased by 11.54%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.79 News SentimentOKYO Pharma has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for OKYO Pharma this week, compared to 1 article on an average week.MarketBeat Follows1 people have added OKYO Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, OKYO Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders40.46% of the stock of OKYO Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.97% of the stock of OKYO Pharma is held by institutions.Read more about OKYO Pharma's insider trading history. Receive OKYO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OKYO Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address OKYO Stock News HeadlinesJapan's Takeda raises full-year profit forecast amid restructuringOctober 31 at 8:21 AM | msn.comOKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conferenceOctober 30 at 9:38 AM | proactiveinvestors.comThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 31, 2024 | Porter & Company (Ad)OKYO Pharma (NASDAQ:OKYO) Earns Buy Rating from HC WainwrightOctober 28 at 4:13 AM | americanbankingnews.comOKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial - ICYMIOctober 26, 2024 | proactiveinvestors.comOKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trialOctober 23, 2024 | proactiveinvestors.comOKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal PainOctober 23, 2024 | globenewswire.comQ2 EPS Estimates for OKYO Pharma Decreased by HC WainwrightOctober 22, 2024 | americanbankingnews.comSee More Headlines OKYO Stock Analysis - Frequently Asked Questions How have OKYO shares performed this year? OKYO Pharma's stock was trading at $1.77 at the start of the year. Since then, OKYO stock has decreased by 33.3% and is now trading at $1.18. View the best growth stocks for 2024 here. When did OKYO Pharma IPO? OKYO Pharma (OKYO) raised $2 million in an initial public offering (IPO) on Tuesday, May 17th 2022. The company issued 625,000 shares at a price of $4.00 per share. How do I buy shares of OKYO Pharma? Shares of OKYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of OKYO Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that OKYO Pharma investors own include Meta Platforms (META), Intel (INTC), NVIDIA (NVDA), C3.ai (AI), Bristol-Myers Squibb (BMY), Energy Transfer (ET) and Ford Motor (F). Company Calendar Today10/31/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OKYO CUSIPN/A CIK1849296 Webwww.okyopharma.com Phone44-20-7495-2379FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+500.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.21 Quick Ratio0.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.20) per share Price / Book-5.83Miscellaneous Outstanding Shares33,836,000Free Float20,146,000Market Cap$39.42 million OptionableNot Optionable Beta-0.06 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:OKYO) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.